Sight Sciences 株価情報 (NASDAQ: SGHT)

最新ニュース Sight Sciences (NASDAQ:SGHT) 株価情報

Sight Sciences

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Sight Sciences Inc

<ul>
<li>AAPL</li>
<li>AMZN</li>
<li>TSLA</li>
<li>BULL</li>
<li>RDDT</li>
<li>GLD</li>
<li>MSTR</li>
<li>NVDA</li>
<li>DE</li>
<li>QQQ</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

AAPL

AMZN

BULL

MSTR

NVDA

RDDT

TSLA

Top 10 Trending Stocks On WallStreetBets As Of May 2, 2025 (Via Swaggy Stocks)

Evercore ISI Group analyst Steve Sakwa maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a In-Line and raises the price target from $297 to $309.

News

Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on Public Storage, Raises Price Target to $309

WIIM

Cooper-Standard Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

FuboTV&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>)&nbsp;reported&nbsp;earnings for the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45162938/fubos-global-streaming-business-exceeded-subscriber-guidance-achieved-revenue-targets-in-q1-2025" rel="noreferrer noopener">first-quarter&nbsp;of 2025</a> on Friday. The stock price declined after the results.
Revenue of the sports-first live TV streaming platform grew 8.1%&nbsp;year over year&nbsp;to $405.96 million, marginally missing the&nbsp;analyst&nbsp;consensus estimate of $415.45 million.
Adjusted EPS loss of 2 cents beat the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate</a> of 9 cents.
Also Read: <a href="https://www.benzinga.com/news/earnings/25/02/44042301/fubotv-projects-subscriber-fall-in-q1-after-q4-topline-growth-stock-tumbles" target="_blank" rel="noreferrer noopener">FuboTV Projects Subscriber Fall In Q1 After Q4 Topline Growth, Stock Tumbles</a>
The company's adjusted EBITDA margin loss stood at .3% versus 9.9% Y/Y. 
North America Streaming:&nbsp;Revenue grew 3.5% Y/Y to $407.9 million, as paid subscribers declined 2.7% Y/Y to 1.47 million. Average revenue per user (ARPU) rose 1.0% Y/Y to $85.37.
Rest of the World Streaming: Revenue was $8.4 million, a 0.4% Y/Y decline, and paid subscribers declined 10.9% Y/Y to 354,000. ARPU grew by 10.9% Y/Y to $7.76.
As of March 31, FuboTV held $327.8 million in cash and equivalents. The company used $(61.99) million in free cash flow in the quarter, compared to $(71.30) million from a year ago.
Outlook:&nbsp;FuboTV expects second-quarter North American revenue of $340 million–$350 million and ROW revenue of $6.5 million-$7.5 million versus consensus of&nbsp;$387.68 million <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst consensus estimate</a>.
Fubo expects 1.55 million-1.59 million total subscribers by the quarter.
It estimates North American subscribers to be 1.225 million-1.255 million, representing a 14% Y/Y decline at the midpoint.
It projects ROW 325,000-335,000 subscribers, representing a 17% Y/Y decline at the midpoint.
Price Action: Fubo stock traded lower by 7.51% at $2.71 premarket at last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/04/44875151/fubo-extends-soccer-reign-in-canada-with-premier-league-renewal" target="_blank" rel="noreferrer noopener">Fubo Extends Soccer Reign In Canada With Premier League Renewal</a></li>
</ul>
Image: Logo courtesy of Fubo

Earnings

Guidance

FUBO

FuboTV Stock Drops After Q1 Subscriber Losses And Lower-Than-Expected Outlook

Cantor Fitzgerald analyst Deepak Mathivanan maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Overweight and raises the price target from $230 to $240.

Cantor Fitzgerald Maintains Overweight on Amazon.com, Raises Price Target to $240

<ul>
<li>It is estimated that by 2030 the prevalence of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in the Canadian general population will increase from 5.2% to 6.5%.1&nbsp;</li>
<li>Left untreated, MASH can progress to serious and even fatal outcomes, such as cirrhosis, liver cancer, and the need for liver transplant.2&nbsp;</li>
</ul>
&nbsp;

Health Canada Accepts Semaglutide 2.4 mg As Supplemental New Drug Submission Under Priority Review Policy

Evercore ISI Group analyst Cory Kasimov maintains Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a In-Line and lowers the price target from $50 to $32.

MRNA

Evercore ISI Group Maintains In-Line on Moderna, Lowers Price Target to $32

TNMG

TNL Mediagene shares are trading lower after the company reported a year-over-year decrease in FY24 EPS results.

<a href="https://x.com/TvAlmasirah/status/1918290745770889474" title="https://x.com/TvAlmasirah/status/1918290745770889474">https://x.com/TvAlmasirah/status/1918290745770889474</a>

Macro Economic Events

Economics

iShares MSCI Israel Capped Investable Market Index Fund

Houthi-Linked Channel, Al Masirah TV, On X Shares Statement Regarding Military Operation Targeting Israeli In Haifa Area

Evercore ISI Group analyst Michael Binetti maintains Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with a In-Line and lowers the price target from $9 to $8.

Evercore ISI Group Maintains In-Line on Kohl's, Lowers Price Target to $8

AMWL

American Well shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance with its midpoint above estimates.

Citigroup analyst Samantha Semenkow initiates coverage on Structure Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) with a Buy rating and announces Price Target of $60.

Initiation

GPCR

Citigroup Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $60

Evercore ISI Group analyst John Dunn maintains Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) with a In-Line and raises the price target from $33 to $35.

Janus Henderson Group plc Ordinary Shares

Evercore ISI Group Maintains In-Line on Janus Henderson Group, Raises Price Target to $35

AIRS

AirSculpt Technologies shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance with its midpoint above estimates.

Evercore ISI Group analyst Vijay Kumar maintains Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) with a In-Line and lowers the price target from $65 to $62.

HOLX

Evercore ISI Group Maintains In-Line on Hologic, Lowers Price Target to $62

PAPL

Pineapple Financial shares are trading lower after the company announced a $1.5 million public offering.

Evercore ISI Group analyst Duane Pfennigwerth maintains Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) with a Outperform and lowers the price target from $175 to $160.

Evercore ISI Group Maintains Outperform on Hyatt Hotels, Lowers Price Target to $160

Exact Sciences Corp.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NYSE">EXAS</a>) on Thursday reported a first-quarter 2025 EPS loss of 21 cents, down from a 37-cent loss a year ago, beating the analyst&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss estimate of 38 cents.</a>
The company reported quarterly sales of $706.78 million, up 11% year over year on a reported and core revenue basis, beating the consensus&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45149849/exact-sciences-announces-first-quarter-2025-results" rel="noreferrer noopener">estimate of $688.64 million</a>.
Screening revenue was $540 million, an increase of 14%, and Precision Oncology's revenue was $166.8 million, an increase of 2%&nbsp;or 4% on a core revenue basis.
"Our strong first quarter results pave the way for 2025 to mark our most transformative year yet," said Kevin Conroy, chairman and CEO. &#8220;With growing momentum in our commercial organization and improved profitability, we raised our full-year outlook and continue to build a foundation for sustained long-term growth."
Guidance: Exact Sciences raised its fiscal 2025 sales guidance from $3.02 billion-3.08 billion to $3.07 billion-3.12 billion versus the consensus of $3.06 billion.
The guidance includes a screening sales forecast of $2.39 billion—$2.43 billion, compared to previous guidance of $2.35 billion—$2.39 billion.
Precision Oncology sales are expected to be $680 million—$695 million, compared to prior guidance of $675 million—$695 million.
The company expects 2025 Adjusted EBITDA of $425 million—$455 million, up from previous guidance of $410 million—$440 million.
&#8220;Simply put, this was a solid first quarter out of the gate and we believe Exact is well positioned to continue to show modest upside throughout the year. This upside, coupled with pipeline catalysts like blood-based CRC screening test data later this summer, keep us positive on the long-term prospects,&#8221; William Blair writes.
Analyst Andrew F. Brackmann added, &#8220;In sum, this was a positive update and helped build support for a bullish thesis that can drive the stock higher over the course of the year. Shares trade at a very compelling forward revenue multiple of 3.5 times, leaving ample room for multiple expansion.&#8221;
William Blair reiterated <a href="https://www.benzinga.com/quote/EXAS/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.
Price Action: At the last check on Friday, EXAS stock was up 11.3% at $52.50 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45158118/analyst-cautions-on-snap-as-meta-and-google-benefit-from-ad-spending-shifts" target="_blank" rel="noreferrer noopener">Analyst Cautions On Snap As Meta And Google Benefit From Ad Spending Shifts</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Health Care

Movers

General

EXAS

Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance

TRUP

Trupanion shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 sales guidance above estimates, and raised its FY25 sales guidance.

Evercore ISI Group analyst Peter Levine maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Outperform and lowers the price target from $55 to $40.

FIVN

Evercore ISI Group Maintains Outperform on Five9, Lowers Price Target to $40

Press Releases

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2024 Financial Highlights

Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

Management

Sight Sciences Appoints Gary Burbach to its Board of Directors

Sight Sciences Announces the Release of its Sustainability Report

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

BWXT

SGHT

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CVRx

Alpha Tau Medical

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Sight Sciences

ニュース

最新ニュース Sight Sciences (NASDAQ:SGHT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル